If FDA says ‘make it so,’ Loxo’s Vitrakvi could see competition from Roche’s entrectinib
The agency set an August PDUFA date for entrectinib, which it gave priority review. It did the same for another Roche drug, polatuzumab vedotin, for high-grade lymphoma.
